Abstract
Objective:
The purpose of this study was to correlate findings on the first follow-up CT after treatment with imatinib in patients with residual or recurrent gastrointestinal stromal tumors (GISTs) with the different types of KIT mutation present at initial resection.
Conclusion:
Residual and recurrent GISTs with KIT mutation of exon 11 deletion more frequently showed both tumor shrinkage and cystic change on 2-month follow-up CT images after the start of imatinib treatment than did other mutation types.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Benzamides
-
Female
-
Follow-Up Studies
-
Gastrointestinal Stromal Tumors / diagnostic imaging*
-
Gastrointestinal Stromal Tumors / drug therapy
-
Gastrointestinal Stromal Tumors / genetics*
-
Humans
-
Imatinib Mesylate
-
Liver Neoplasms / secondary
-
Lung Neoplasms / secondary
-
Male
-
Middle Aged
-
Mutation
-
Neoplasm Recurrence, Local / diagnostic imaging*
-
Neoplasm Seeding
-
Neoplasm, Residual / diagnostic imaging*
-
Peptide Fragments / therapeutic use
-
Piperazines / therapeutic use
-
Proto-Oncogene Proteins c-kit / genetics
-
Pyrimidines / therapeutic use
-
Receptor, Platelet-Derived Growth Factor alpha / genetics
-
Retrospective Studies
-
Splenic Neoplasms / secondary
-
Tomography, X-Ray Computed
Substances
-
Benzamides
-
Peptide Fragments
-
Piperazines
-
Pyrimidines
-
protein kinase inhibitor peptide (5-24)
-
Imatinib Mesylate
-
Proto-Oncogene Proteins c-kit
-
Receptor, Platelet-Derived Growth Factor alpha